Over a period of 28 years, Li Xuemei Research Group comprehensively has used such disciplinary theories as pharmacodynamics,natural pharmaceutical chemistry to extract monomers of sophoridine alkaloids from Chinese herbal medicine Sophora alopecuroides.The purity reaches above 98%.
The pharmacological studies have proven that sophoridine has stable 30-60% inhibitory rate for animal-transplanted tumor S-180,low toxicity;no teratogenic effects,no mutagenicity. It has certain direct killing effect on cancer cells.The in vivo process conforms to the two auriculo-ventricular model, distributed widely and quickly,could been eliminated rapidly,and could been excreted by kidneys with prototypes.
The clinical trial resultsof the 363 cases in the10 hospitals nation wide have proven that sophoridine has a significant (above70%) efficacy for malignant trophoblastic tumors, and has certain（16-20%）efficacy for malignant lymphoma and gastrointestinal tumors. Sophoridine,withlow toxic and adverse effects, and no significant effect on major organs,does not suppress hemopoiesis function of marrow,which is better than the existing chemotherapeutic anti-cancer drugsin this respect. In 2007,the school transferred the exclusive production right of sophoridine toTonghua Fangda Pharmaceutical Co, Ltd. Since the puttingin the market, sophoridine，with obvious efficacy，has been successfully used in well-known hospitals in Beijing, Shanghai, etc.The results won the first and second prize of Jiangxi Provincial Prize for Progress in Science and Technology in 2003 and 2007 respectively.